Related Experiment Video

Updated: Jun 16, 2026

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

A new class of molecular targeted radioprotectors: GSK-3beta inhibitors

Dinesh K Thotala1, Ling Geng, Amy K Dickey

  • 1Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA.

International Journal of Radiation Oncology, Biology, Physics
|February 2, 2010
PubMed
Abstract

Insights

Small-molecule inhibitors of glycogen synthase kinase 3beta (GSK-3beta) show promise as radioprotective agents. These GSK-3beta inhibitors significantly improve survival and reduce intestinal injury after radiation exposure in mice.

Area of Science:

  • Radiation oncology
  • Molecular biology
  • Drug discovery

Background:

  • Radiation therapy is a cornerstone of cancer treatment, but it can cause significant intestinal injury.
  • Developing effective radioprotective agents is crucial for improving patient outcomes and quality of life during radiation therapy.
  • Glycogen synthase kinase 3beta (GSK-3beta) is implicated in cellular responses to stress and injury.

Purpose of the Study:

  • To investigate the potential of small-molecule inhibitors of GSK-3beta as radioprotective agents.
  • To evaluate the efficacy of GSK-3beta inhibitors in attenuating radiation-induced intestinal injury in vivo and in vitro.
  • To elucidate the molecular mechanisms underlying the radioprotective effects of GSK-3beta inhibitors.

Main Methods:

  • Survival studies in C57BL/6J mice exposed to varying doses of radiation.
  • Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay and immunohistochemical staining for apoptosis markers (Bax, Bcl-2) in mouse intestinal tissues.
  • Clonogenic survival assays, apoptosis assays (Annexin V, 4',6-diamidino-2-phenylindole), and immunoblot analysis in rat intestinal epithelial IEC-6 cells.

Main Results:

  • Pretreatment with GSK-3beta inhibitors (SB415286, SB216763) significantly improved mouse survival after irradiation.
  • Inhibitors reduced radiation-induced apoptosis in intestinal crypts, evidenced by decreased TUNEL- and Bax-positive cells and increased Bcl-2-positive cells.
  • In vitro studies showed increased clonogenic survival of irradiated IEC-6 cells treated with GSK-3beta inhibitors, due to attenuated apoptosis.

Conclusions:

  • Small-molecule GSK-3beta inhibitors demonstrate significant radioprotective effects against intestinal injury in both cell culture and animal models.
  • The protective mechanism involves the regulation of apoptosis through modulation of Bcl-2, Bax, and caspase 3.
  • GSK-3beta inhibitors represent a promising therapeutic strategy to mitigate the adverse effects of intestinal irradiation, potentially improving patient quality of life.

More Related Videos

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...